Estimated medication costs of primary TNFα antagonist failure in patients with rheumatoid arthritis

Joint Bone Spine

Volumn 79, Issue 4, 2012, Pages 421-422

  Rose, Estelle ^a   Lequerré, Thierry ^a   Pouplin, Sophie ^a   Daragon, Alain ^a   Le Loët, Xavier ^a   Vittecoq, Olivier ^a  

^a UNIVERSITÉ DE ROUEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; VIDAL;

DRUG COST; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; LABORATORY TEST; LETTER; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG COSTS; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863200095     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2012.01.017     Document Type: Letter

References (9)

1. Guillemin F., Saraux A., Guggenbuhl P., et al. Prevalence of rheumatoid arthritis in France: 2001. Ann Rheum Dis 2005, 64:1427-1430.
2. Nixon R., Bansback N., Brennan A. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) 2007, 46:1140-1147.
3. Combe B. Switching between anti-TNF alpha agents: what is the evidence?. Joint Bone Spine 2004, 71:169-171.
4. Hyrich K.L., Lunt M., Watson K.D., et al. Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007, 56:13-20.
5. Rat A.-C., Boissier M.-C. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine 2004, 71:518-524.
6. Saraux A., Gossec L., Goupille P., et al. Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France. Rheumatology (Oxford) 2010, 49:733-740.
7. Cimmino M.A., Leardini G., Salaffi F., et al. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach. Clin Exp Rheumatol 2011, 29:633-641.
8. Lequerré T., Gauthier-Jauneau A.C., Bansard C., et al. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther 2006, 8:R105-R115.
9. Trocmé C., Marotte H., Baillet A., et al. Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1328-1333.